APEX: Hopeful Sign Despite Betrixaban Miss for VTE PreventionAPEX: Hopeful Sign Despite Betrixaban Miss for VTE Prevention

The novel oral agent didn't win out over enoxaparin in the trial's primary cohort but did in the larger overall cohort; the later finding was exploratory but convincing nonetheless, say researchers. Heartwire from Medscape

Source: Medscape Medical News Headlines - June 7, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news